Latham & Watkins advised IDEAYA Biosciences, while Davis Polk advised the underwriters in the offering.
IDEAYA Biosciences, Inc. executed its public offering of 5,333,333 shares of common stock at $17.25 per share, which included 695,652 shares from the full exercise of the underwriters’ option to purchase additional shares, for total gross proceeds of $92 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “IDYA.”
J.P. Morgan Securities LLC, Citigroup Global Markets Inc., Jefferies LLC, and Guggenheim Securities, LLC acted as underwriters for the offering.
Based in South San Francisco, California, IDEAYA is a clinical stage oncology-focused precision medicine company developing targeted therapeutics for patients selected using molecular diagnostics across multiple oncology indications.
Latham & Watkins advised IDEAYA Biosciences with a team led by Mark V. Roeder (Picture).
The Davis Polk corporate team included partner Alan F. Denenberg and associates Jonathan Bye, Paula Gergen and Lawrence Edward Traylor Jr. The tax team included partner Po Sit and associate Ben Levenback. The intellectual property and technology transactions team included partner David R. Bauer and associate S. Dream Montgomery. Counsel Marcie A. Goldstein provided FINRA advice.
Involved fees earner: David Bauer – Davis Polk & Wardwell; Jonathan Bye – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Paula Gergen – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Ben Levenback – Davis Polk & Wardwell; S. Dream Montgomery – Davis Polk & Wardwell; Po Sit – Davis Polk & Wardwell; Lawrence Edward Traylor Jr. – Davis Polk & Wardwell; Mark Roeder – Latham & Watkins;